rs199473677
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_025099.6(CTC1):βc.2831delβ(p.Pro944LeufsTer7) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000211 in 1,614,126 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00035 ( 0 hom., cov: 32)
Exomes π: 0.00020 ( 0 hom. )
Consequence
CTC1
NM_025099.6 frameshift
NM_025099.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.393
Genes affected
CTC1 (HGNC:26169): (CST telomere replication complex component 1) This gene encodes a component of the CST complex. This complex plays an essential role in protecting telomeres from degradation. This protein also forms a heterodimer with the CST complex subunit STN1 to form the enzyme alpha accessory factor. This enzyme regulates DNA replication. Mutations in this gene are the cause of cerebroretinal microangiopathy with calcifications and cysts. Alternate splicing results in both coding and non-coding variants. [provided by RefSeq, Mar 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-8230395-AG-A is Pathogenic according to our data. Variant chr17-8230395-AG-A is described in ClinVar as [Pathogenic]. Clinvar id is 31000.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-8230395-AG-A is described in Lovd as [Pathogenic]. Variant chr17-8230395-AG-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CTC1 | NM_025099.6 | c.2831del | p.Pro944LeufsTer7 | frameshift_variant | 17/23 | ENST00000651323.1 | NP_079375.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CTC1 | ENST00000651323.1 | c.2831del | p.Pro944LeufsTer7 | frameshift_variant | 17/23 | NM_025099.6 | ENSP00000498499 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000362 AC: 55AN: 152136Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
55
AN:
152136
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000409 AC: 102AN: 249486Hom.: 0 AF XY: 0.000369 AC XY: 50AN XY: 135350
GnomAD3 exomes
AF:
AC:
102
AN:
249486
Hom.:
AF XY:
AC XY:
50
AN XY:
135350
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000196 AC: 287AN: 1461872Hom.: 0 Cov.: 32 AF XY: 0.000186 AC XY: 135AN XY: 727240
GnomAD4 exome
AF:
AC:
287
AN:
1461872
Hom.:
Cov.:
32
AF XY:
AC XY:
135
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000355 AC: 54AN: 152254Hom.: 0 Cov.: 32 AF XY: 0.000470 AC XY: 35AN XY: 74438
GnomAD4 genome
AF:
AC:
54
AN:
152254
Hom.:
Cov.:
32
AF XY:
AC XY:
35
AN XY:
74438
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cerebroretinal microangiopathy with calcifications and cysts 1 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 12, 2023 | Variant summary: CTC1 c.2831delC (p.Pro944LeufsX7) results in a premature termination codon, predicted to cause absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant allele was found at a frequency of 0.00041 in 249486 control chromosomes in gnomAD. This frequency is not significantly higher than estimated for a pathogenic variant in CTC1 causing Cerebroretinal Microangiopathy With Calcifications And Cysts 1 (0.00041 vs 0.0011), allowing no conclusion about variant significance. c.2831delC has been reported in trans along with second disease-causing variants in multiple individuals affected with Cerebroretinal Microangiopathy With Calcifications And Cysts 1 (example: Polvi_2012). These data indicate that the variant is very likely to be associated with disease. The following publication have been ascertained in the context of this evaluation (PMID: 22387016). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 (all pathogenic). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 09, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 21, 2020 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Published functional studies demonstrate a damaging effect: protein truncation and anomalous telomere replication (Gu 2013); This variant is associated with the following publications: (PMID: 23869908, 31028847, 22387016, 31589614) - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Mar 30, 2020 | DNA sequence analysis of the CTC1 gene demonstrated a 1 base pair deletion in exon 17, c.2831del. This pathogenic sequence change results in an amino acid frameshift and creates a premature stop codon 7 amino acids downstream of the mutation, p.Pro944Leufs*7. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated CTC1 protein with potentially abnormal function. This sequence change has been described in the gnomAD database with a frequency of 0.28% in the Finnish sub-population (dbSNP rs779650334). The p.Pro944Leufs*7 change has been reported in several unrelated Finnish individuals with cerebroretinal microangiopathy with calcifications and cysts (PMID: 22387016). Other frameshift deletions have been reported downstream of this sequence change in individuals with cerebroretinal microangiopathy with calcifications and cysts and paroxysmal nocturnal haemoglobinuria (PMIDs: 22387016, 30891747). Functional studies have demonstrated loss of protein function in the presence of a truncating variant in the homologous residue in mice (p.Pro939*) (PMID: 23869908).These collective evidences indicate that this is a pathogenic sequence change. - |
Coats plus syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 14, 2018 | The p.Pro944fs variant in CTC1 has been reported in the compound heterozygous st ate in at least 5 individuals with cerebroretinal microangiopathy with calcifica tions and cysts (CRMCC, also known as Coats plus syndrome; Polvi 2012). It has a lso been identified in 0.3% (73/25790) of Finnish chromosomes by the Genome Aggr egation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs199473677). This variant is predicted to cause a frameshift, which alters the protein?s amin o acid sequence beginning at position 944 and leads to a premature termination c odon 7 amino acids downstream. This alteration is then predicted to lead to a tr uncated or absent protein. In vitro functional studies support that this variant impacts protein function (Gu 2013). Multiple loss of function variants in the C TC1 gene have been reported in individuals with CRMCC; however, to date, there a re no individuals with 2 null variants, suggesting that biallelic loss-of-functi on mutations might be incompatible with life (Anderson 2012; Polvi 2012). In sum mary, this variant is pathogenic. ACMG/AMP Criteria applied: PVS1; PP4; PM3_Supp orting. - |
CTC1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 01, 2024 | The CTC1 c.2831delC variant is predicted to result in a frameshift and premature protein termination (p.Pro944Leufs*7). This variant has been reported as pathogenic for autosomal recessive cerebroretinal microangiopathy with calcifications and cysts (Polvi et al. 2012. PubMed ID: 22387016). This variant is reported in 0.28% of alleles in individuals of European (Finnish) descent in gnomAD. Frameshift variants in CTC1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Dyskeratosis congenita Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This sequence change creates a premature translational stop signal (p.Pro944Leufs*7) in the CTC1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CTC1 are known to be pathogenic (PMID: 22267198, 22387016). This variant is present in population databases (rs199473677, gnomAD 0.3%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individual(s) with cerebroretinal microangiopathy with calcifications and cysts (PMID: 22387016). ClinVar contains an entry for this variant (Variation ID: 31000). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at